{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"tyrosinemia-type-iii","columns":[{"gene":"","key":"population-9a4bdcaec00341bb8922","label":"Tyrosinemia, type III","mondoId":"MONDO:0010162","onsetQualifier":null,"originColumnKey":"MONDO:0010162/OMIM:276710","originalViews":[{"key":"MONDO:0010162/OMIM:276710","label":"Tyrosinemia, type III","scopeLabel":"OMIM:276710","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["14ad0a7ddeaba2d63dba198d1a9ad5fdd99af8f688b5ee9572dfab671f36303e","1da56bd9df5884cffdd5d10b10355a0cb5952d4766e649583cb77c4324c38fc4","6c85201adf22275004d1b5205cfb44ce40c378c21362a584a0583465900a5f01","9943689bcc3de9ccf8f7ee371aaded68c9da3d9f6064830556ce3391a550f1b0","9fa254d9a4c26179e059604f3d4b4febee88298ceb783f6f98c3e2b5fb4470df","d3c5f1789f73746c348de9eb4d879aed8392234714d7cfd3f1477570e4e98a7a","df07ca08ee04db39869ca9b1fbe51f9e8a9e08bfc81770e5345950e564689d07","dfd583afb932263c7861f579dceee6bc2f8ed43b4913d92cfea361a286974f48"],"recordQualifiers":{},"scopeLabel":"OMIM:276710","sourceIds":["OMIM:276710"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-9a4bdcaec00341bb8922"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0003607","HP:0003161","HP:0002910","HP:0001263","HP:0003231","HP:0001256","HP:0001250"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":8,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":8,"sourceGroups":{"omim":1,"published":7}},"features":[{"hpoId":"HP:0003607","label":"4-hydroxyphenylacetic aciduria","primary":true},{"hpoId":"HP:0003161","label":"4-Hydroxyphenylpyruvic aciduria","primary":true},{"hpoId":"HP:0002910","label":"Elevated circulating hepatic transaminase concentration","primary":true},{"hpoId":"HP:0001263","label":"Global developmental delay","primary":true},{"hpoId":"HP:0003231","label":"Hypertyrosinemia","primary":true},{"hpoId":"HP:0001256","label":"Mild intellectual disability","primary":true},{"hpoId":"HP:0001250","label":"Seizure","primary":true},{"hpoId":"HP:0010864","label":"Severe intellectual disability","primary":false}],"ledeHtml":"Tyrosinemia type 3 is a genetic disorder characterized by elevated blood levels of the amino acid tyrosine, a building block of most proteins. This condition is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase, one of the enzymes required for the multi-step process that breaks down tyrosine. This enzyme shortage is caused by genetic changes in the HPD gene. Characteristic features include intellectual disability, seizures, and periodic loss of balance and coordination (intermittent ataxia). Tyrosinemia type 3 is inherited in an autosomal recessive manner.","mondoId":"MONDO:0010162","node":{"canonicalSlug":"tyrosinemia-type-iii","comparisons":[{"documentSha256":"9e8185d674eaef65f59d3441ebee524b95f0674d9b6014b4433e55168452d58a","key":"legacy-tyrosinemia","kind":"legacy","label":"tyrosinemia","memberIds":["MONDO:0004741","MONDO:0010160","MONDO:0010161","MONDO:0010162"],"mondoId":"MONDO:0004741","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/tyrosinemia.9e8185d674eaef65f59d3441ebee524b95f0674d9b6014b4433e55168452d58a.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Tyrosinemia type III","originalSourceId":"ORPHA:69723","paragraphs":["Tyrosinemia type 3 is a genetic disorder characterized by elevated blood levels of the amino acid tyrosine, a building block of most proteins. This condition is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase, one of the enzymes required for the multi-step process that breaks down tyrosine. This enzyme shortage is caused by genetic changes in the HPD gene. Characteristic features include intellectual disability, seizures, and periodic loss of balance and coordination (intermittent ataxia). Tyrosinemia type 3 is inherited in an autosomal recessive manner."],"rawAttribution":"MONDO:0010162","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-25T03:41:04Z","upstream":"GARD:0010332","url":"https://rarediseases.info.nih.gov/diseases/10332"},"ownColumnKeys":["population-9a4bdcaec00341bb8922"],"publication":"published","relationships":[{"kind":"parent","label":"tyrosinemia","mondoId":"MONDO:0004741","slug":"tyrosinemia"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"count","key":"14ad0a7ddeaba2d63dba198d1a9ad5fdd99af8f688b5ee9572dfab671f36303e","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:276710","disease_name":"Tyrosinemia, type III","evidence":"PCS","frequency_raw":"0/5","hpo_id":"HP:0002910","is_excluded":true,"label":"Elevated circulating hepatic transaminase concentration","onset_id":null,"reference":"PMID:10942115","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"1da56bd9df5884cffdd5d10b10355a0cb5952d4766e649583cb77c4324c38fc4","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:276710","disease_name":"Tyrosinemia, type III","evidence":"IEA","frequency_raw":"1/5","hpo_id":"HP:0001256","is_excluded":false,"label":"Mild intellectual disability","onset_id":null,"reference":"OMIM:276710","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"6c85201adf22275004d1b5205cfb44ce40c378c21362a584a0583465900a5f01","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:276710","disease_name":"Tyrosinemia, type III","evidence":"PCS","frequency_raw":"5/5","hpo_id":"HP:0003231","is_excluded":false,"label":"Hypertyrosinemia","onset_id":null,"reference":"PMID:10942115","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"9943689bcc3de9ccf8f7ee371aaded68c9da3d9f6064830556ce3391a550f1b0","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:276710","disease_name":"Tyrosinemia, type III","evidence":"PCS","frequency_raw":"4/4","hpo_id":"HP:0003607","is_excluded":false,"label":"4-hydroxyphenylacetic aciduria","onset_id":null,"reference":"PMID:10942115","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"9fa254d9a4c26179e059604f3d4b4febee88298ceb783f6f98c3e2b5fb4470df","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:276710","disease_name":"Tyrosinemia, type III","evidence":"PCS","frequency_raw":"3/5","hpo_id":"HP:0001263","is_excluded":false,"label":"Global developmental delay","onset_id":null,"reference":"PMID:10942115","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"d3c5f1789f73746c348de9eb4d879aed8392234714d7cfd3f1477570e4e98a7a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:276710","disease_name":"Tyrosinemia, type III","evidence":"PCS","frequency_raw":"4/4","hpo_id":"HP:0003161","is_excluded":false,"label":"4-Hydroxyphenylpyruvic aciduria","onset_id":null,"reference":"PMID:10942115","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"df07ca08ee04db39869ca9b1fbe51f9e8a9e08bfc81770e5345950e564689d07","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:276710","disease_name":"Tyrosinemia, type III","evidence":"PCS","frequency_raw":"0/5","hpo_id":"HP:0001250","is_excluded":true,"label":"Seizure","onset_id":null,"reference":"PMID:10942115","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"dfd583afb932263c7861f579dceee6bc2f8ed43b4913d92cfea361a286974f48","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:276710","disease_name":"Tyrosinemia, type III","evidence":"PCS","frequency_raw":"1/5","hpo_id":"HP:0010864","is_excluded":false,"label":"Severe intellectual disability","onset_id":null,"reference":"PMID:10942115","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/10332\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0010162\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>GARD:0010332</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Tyrosinemia type 3 is a genetic disorder characterized by elevated blood levels of the amino acid tyrosine, a building block of most proteins. This condition is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase, one of the enzymes required for the multi-step process that breaks down tyrosine. This enzyme shortage is caused by genetic changes in the HPD gene. Characteristic features include intellectual disability, seizures, and periodic loss of balance and coordination (intermittent ataxia). Tyrosinemia type 3 is inherited in an autosomal recessive manner.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/10332\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"tyrosinemia-type-iii","sourceDocuments":[{"name":"GARD: Tyrosinemia type III","reviewed":null,"source_release":"2026-10-25T03:41:04Z","url":"https://rarediseases.info.nih.gov/diseases/10332"},{"name":"MONDO: tyrosinemia type III","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0010162"}],"sourceNote":"","synonyms":["4-alpha hydroxyphenylpyruvate dioxygenase deficiency","4-alpha hydroxyphenylpyruvic acid oxidase deficiency","tyrosinemia due to 4-hydroxyphenylpyruvate dioxygenase deficiency","tyrosinemia due to 4-hydroxyphenylpyruvic acid oxidase deficiency","tyrosinemia due to HPD deficiency","tyrosinemia type 3","tyrosinemia type III","tyrosinemia, type III","TYRSN3"],"takeawayHtml":"","title":"tyrosinemia type III"},"schemaVersion":1}
